Market Closed -
Nasdaq
04:00:00 2024-05-10 pm EDT
|
5-day change
|
1st Jan Change
|
1.28
USD
|
+1.59%
|
|
-1.54%
|
-15.23%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
978.4
|
2,647
|
3,276
|
965.9
|
1,167
|
892.1
|
-
|
-
|
Enterprise Value (EV)
1 |
978.4
|
2,647
|
3,276
|
965.9
|
1,167
|
892.1
|
892.1
|
892.1
|
P/E ratio
|
-2.77
x
|
79
x
|
-96.2
x
|
-2.72
x
|
-6.04
x
|
-3.43
x
|
-4.03
x
|
-8
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
1.08
x
|
1.84
x
|
1.85
x
|
0.96
x
|
1.35
x
|
1.25
x
|
1.18
x
|
1.04
x
|
EV / Revenue
|
1.08
x
|
1.84
x
|
1.85
x
|
0.96
x
|
1.35
x
|
1.25
x
|
1.18
x
|
1.04
x
|
EV / EBITDA
|
-7.42
x
|
24
x
|
91.5
x
|
-6.1
x
|
-16.2
x
|
-11.1
x
|
64.2
x
|
11.8
x
|
EV / FCF
|
-5.28
x
|
457
x
|
530
x
|
-
|
-26.2
x
|
-7.05
x
|
-14.3
x
|
-60.7
x
|
FCF Yield
|
-18.9%
|
0.22%
|
0.19%
|
-
|
-3.81%
|
-14.2%
|
-6.98%
|
-1.65%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
665,601
|
670,000
|
681,099
|
772,686
|
773,057
|
696,992
|
-
|
-
|
Reference price
2 |
1.470
|
3.950
|
4.810
|
1.250
|
1.510
|
1.280
|
1.280
|
1.280
|
Announcement Date
|
2/26/20
|
2/18/21
|
2/24/22
|
2/23/23
|
2/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
901.9
|
1,435
|
1,775
|
1,004
|
863.5
|
715.2
|
754
|
854.5
|
EBITDA
1 |
-131.8
|
110.1
|
35.8
|
-158.4
|
-72
|
-80.3
|
13.9
|
75.7
|
EBIT
1 |
-274.1
|
57.7
|
18.7
|
-226.3
|
-157
|
-239.3
|
-207.7
|
-117.3
|
Operating Margin
|
-30.39%
|
4.02%
|
1.05%
|
-22.54%
|
-18.18%
|
-33.46%
|
-27.55%
|
-13.73%
|
Earnings before Tax (EBT)
1 |
-304.9
|
48.7
|
-14
|
-391.5
|
-184.4
|
-266.1
|
-228.4
|
-123.3
|
Net income
1 |
-314.9
|
30.6
|
-30.1
|
-328.4
|
-188.8
|
-264.7
|
-229.5
|
-117.2
|
Net margin
|
-34.92%
|
2.13%
|
-1.7%
|
-32.7%
|
-21.86%
|
-37.02%
|
-30.43%
|
-13.72%
|
EPS
2 |
-0.5300
|
0.0500
|
-0.0500
|
-0.4600
|
-0.2500
|
-0.3733
|
-0.3180
|
-0.1600
|
Free Cash Flow
1 |
-185.3
|
5.794
|
6.181
|
-
|
-44.47
|
-126.6
|
-62.3
|
-14.7
|
FCF margin
|
-20.54%
|
0.4%
|
0.35%
|
-
|
-5.15%
|
-17.7%
|
-8.26%
|
-1.72%
|
FCF Conversion (EBITDA)
|
-
|
5.26%
|
17.27%
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
18.93%
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/26/20
|
2/18/21
|
2/24/22
|
2/23/23
|
2/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
401.3
|
329.2
|
309.9
|
179.7
|
185.4
|
237.6
|
265.4
|
178.6
|
181.9
|
173.7
|
184.7
|
176.7
|
180
|
173.5
|
182.6
|
EBITDA
1 |
-50.7
|
-50.5
|
-3.1
|
-67.2
|
-37.5
|
-9
|
28.5
|
-44
|
-47.6
|
-50.04
|
-18.2
|
-8.7
|
-
|
-
|
-
|
EBIT
1 |
-63.1
|
-72.4
|
-10.7
|
-87.8
|
-55.3
|
-30.6
|
7
|
-64.4
|
-69.1
|
-71.47
|
-59.2
|
-55.71
|
-52.92
|
-47.77
|
-44.47
|
Operating Margin
|
-15.72%
|
-21.99%
|
-3.45%
|
-48.86%
|
-29.83%
|
-12.88%
|
2.64%
|
-36.06%
|
-37.99%
|
-41.15%
|
-32.05%
|
-31.53%
|
-29.4%
|
-27.53%
|
-24.36%
|
Earnings before Tax (EBT)
1 |
-65.8
|
-76.6
|
-86.3
|
-126.4
|
-102.2
|
-17
|
-16.5
|
-78.4
|
-72.5
|
-83.18
|
-65.72
|
-61.61
|
-62.3
|
-51.2
|
-47.95
|
Net income
1 |
-73.8
|
-55.4
|
-101.7
|
-86.1
|
-85.2
|
-18.3
|
-19.6
|
-84.5
|
-66.5
|
-81.84
|
-65.54
|
-61.69
|
-52.6
|
-50.94
|
-47.72
|
Net margin
|
-18.39%
|
-16.83%
|
-32.82%
|
-47.91%
|
-45.95%
|
-7.7%
|
-7.39%
|
-47.31%
|
-36.56%
|
-47.12%
|
-35.49%
|
-34.92%
|
-29.22%
|
-29.35%
|
-26.14%
|
EPS
2 |
-0.1100
|
-0.0800
|
-0.1400
|
-0.1100
|
-0.1100
|
-0.0200
|
-0.0300
|
-0.1100
|
-0.0900
|
-0.1200
|
-0.0950
|
-0.0867
|
-0.0975
|
-0.0733
|
-0.0700
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/24/22
|
5/9/22
|
8/4/22
|
11/8/22
|
2/23/23
|
5/3/23
|
8/3/23
|
11/6/23
|
2/27/24
|
5/7/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-185
|
5.79
|
6.18
|
-
|
-44.5
|
-127
|
-62.3
|
-14.7
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
12.7
|
33.7
|
32.2
|
-
|
16.3
|
18.5
|
32
|
35
|
Capex / Sales
|
1.41%
|
2.35%
|
1.81%
|
-
|
1.88%
|
2.58%
|
4.24%
|
4.1%
|
Announcement Date
|
2/26/20
|
2/18/21
|
2/24/22
|
2/23/23
|
2/27/24
|
-
|
-
|
-
|
Last Close Price
1.28
USD Average target price
4.25
USD Spread / Average Target +232.03% Consensus |
1st Jan change
|
Capi.
|
---|
| -15.23% | 892M | | -16.58% | 8.49B | | +58.90% | 4.08B | | -39.78% | 2.42B | | -10.33% | 2.42B | | -8.91% | 2.33B | | -2.53% | 2.01B | | -19.90% | 1.53B | | -38.30% | 1.26B | | +2.19% | 1.07B |
Medical & Diagnostic Laboratories
|